Pulse Biosciences appoints Maria Sainz to Board of Directors and Audit Committee

PULSE BIOSCIENCES, INC.

Maria Sainz elected to Pulse Biosciences Board and Audit Committee effective January 8, 2026.
Sainz brings over 30 years of healthtech experience; currently CEO of Hyperfine, Inc. (NASDAQ: HYPR).
Initial stock option grant of 50,000 shares; annual retainer of $55,000 plus $13,000 for Audit Committee.
Previously CEO of Concentric Medical, Aegea Medical, CardioKinetix; leadership at Guidant and Boston Scientific.
Serves on boards of Shockwave Medical (SWAV), Spectranetics (SPNC), Avanos (AVNS), Orthofix (OFIX).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.